Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech/ Biodefense Sector Trading Alert ;Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA

|Includes: ALT, PLX, SIGA Technologies Inc. (SIGA)
Biotech/ Biodefense Sector Trading Alert 
Point Roberts, WA- April 8, 2011 -, a leader in investor sector research including Biotech and Biodefense Stocks issues a trading alert on the sector for morning trading April 8th. Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX and (NasdaqGM: SIGA ).
The iShares Nasdaq Biotechnology Index (NasdaqGM: IBB ) is trading up at 102.37, up 0.19 (0.19%).
Biotech/ Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at$0.12, up 0.01 (4.35%)
Dynasil Corporation (NASDAQ GM: DYSL) trading at$ 4.35, up 0.02 (0.46%)
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $24.70, down 0.04 (0.16%)
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.21, down 0.07 (2.12%)
Protalix BioTherapeutics, Inc. (AMEX: PLX ) trading at $6.63, up 0.20 (3.11%)  
Siga Technologies (NasdaqGM: SIGA ) trading at $13.39, up 0.08 (0.60%) 10:32AM EDT
Research more Biodfense stocks at
Research Biotech Stocks at
Daily Finance’s recent article, “Inside Wall Street: Looking to the Bio-Defense Sector as Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a number of companies emerged to develop protective biodefense drugs and products. But with the waning of dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change
Biotech/ Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD), Protalix BioTherapeutics, Inc. (AMEX: PLX )
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
James A. Joyce
Chairman, CEO
858.459.7800 x301
Recent News: Shareholder Letter
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on
Get added to the company’s news alerts:
Protalix BioTherapeutics, Inc. (AMEX: PLX )
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx™. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner in an environment free of mammalian components and viruses. Protalix's lead compound taliglucerase alfa, an enzyme replacement therapy for the treatment of Gaucher disease, completed Phase III development. To date, marketing applications have been submitted for taliglucerase alfa in the United States, European Union, Brazil and Israel. Protalix's development pipeline also includes: PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; and pr-antiTNF, a biosimilar version of etanercept (Enbrel™) for the treatment of rheumatoid arthritis. is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical (OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 -
Source -